4.91

2.30% -0.08

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$4.99

Offen:

$4.96

24-Stunden-Volumen:

2,362

Relative Volume:

0.01

Marktkapitalisierung:

$41.58M

Einnahmen:

$120.77M

Nettoeinkommen (Verlust:

$32.69M

KGV:

1.6846

EPS:

2.9146

Netto-Cashflow:

$-50.94M

1W Leistung:

-2.30%

1M Leistung:

+6.21%

6M Leistung:

-67.95%

1J Leistung:

-34.30%

1-Tages-Spanne:

$4.885

$4.97

1-Wochen-Bereich:

$4.75

$5.30

52-Wochen-Spanne:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (619)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2026-05-21

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	4.885	42.48M	120.77M	32.69M	-50.94M	2.9146
VRTX Vertex Pharmaceuticals Inc	431.26	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.07	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	779.07	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	306.65	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	300.22	33.17B	5.36B	287.73M	924.18M	2.5229

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Herabstufung	Canaccord Genuity	Buy → Hold
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

09:30 AM

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

09:30 AM

09:00 AM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - PR Newswire

09:00 AM

08:00 AM

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

08:00 AM

Apr 27, 2026

Shareholders that lost money on Atara Biotherapeutics, - GlobeNewswire

Apr 27, 2026

Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - GlobeNewswire Inc.

Apr 27, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire

Apr 27, 2026

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire

Apr 27, 2026

2026-04-27 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 27, 2026

Apr 26, 2026

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 26, 2026

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile

Apr 26, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with ... - Black Hills Pioneer

Apr 26, 2026

Apr 25, 2026

Pomerantz LLP Files Investor Lawsuit Against Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire

Apr 25, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - Scott Coop

Apr 25, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - ACCESS Newswire

Apr 25, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus

Apr 25, 2026

Apr 24, 2026

Atara Biotherapeutics (NASDAQ: ATRA) sets 2026 virtual meeting and equity plan vote - Stock Titan

Apr 24, 2026